Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTX2-7
- Development stage
- Preclinical
- Lead developer
- OssiFi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OTX2-7 is an investigational oral small molecule sclerostin inhibitor being developed by OssiFi for the treatment of bone disorders, including osteoporosis and osteogenesis imperfecta, as well as the prevention of bone fractures in patients with low bone density. Sclerostin is a glycoprotein secreted by osteocytes that acts as a negative regulator of bone formation by inhibiting the Wnt/LRP signaling pathway. By blocking sclerostin, OTX2-7 is designed to stimulate bone formation (anabolic effect) and improve bone strength, offering an oral alternative to injectable anti-sclerostin monoclonal antibodies.
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on OTX2-7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OTX2-7.